Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen
Sign Up to like & getrecommendations! Published in 2024 at "Nature Communications"
DOI: 10.1038/s41467-024-50781-4
Abstract: TBI-223, a novel oxazolidinone for tuberculosis, is designed to provide improved efficacy and safety compared to linezolid in combination with bedaquiline and pretomanid (BPaL). We aim to optimize the dosing of TBI-223 within the BPaL… read more here.
Keywords: enhanced therapeutic; tbi 223; optimization tbi; compared linezolid ... See more keywords
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
Sign Up to like & getrecommendations! Published in 2023 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00035-23
Abstract: A regimen comprised of bedaquiline (BDQ, or B), pretomanid, and linezolid (BPaL) is the first oral 6-month regimen approved by the U.S. Food and Drug Administration and recommended by the World Health Organization for the… read more here.
Keywords: tuberculosis; tbaj 587; tbi 223; drug ... See more keywords
Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants
Sign Up to like & getrecommendations! Published in 2025 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01542-24
Abstract: ABSTRACT TBI-223 is an oxazolidinone antibiotic under clinical development for the treatment of tuberculosis. Preclinical data indicate potent antituberculosis activity and a potentially improved safety profile over linezolid. In a single-ascending dose study and a… read more here.
Keywords: tolerability safety; ascending dose; tbi 223; pharmacokinetics tolerability ... See more keywords